Skip to main content

The Steven Coutre Review of the 63rd Annual American Society of Hematology Meeting

Sponsored by

This event is over.

Event Details:

The 2022 Stanford Review of the 63rd Annual ASH Conference has been renamed in remembrance of the late Dr. Steven Coutre (1959-2021), who is deeply missed as an outstanding leader, educator, and investigator in the field of malignant hematology.  The conference will highlight cutting-edge research and data on hematologic disorders presented at the conference, as well as provide participants with updated treatment algorithms and strategies for optimizing the care of their patients. The 2022 Stanford Review will utilize a variety of learning modalities, including case studies, panel discussions, and audience response questions, to facilitate meaningful interactions between expert faculty presenters and symposium participants. This webinar will showcase important breakthroughs in the hematology field and improvements in diagnosis and treatment that can be implemented in daily practice.

Registration

Registration fee includes course materials and certificate of participation.  Webinar information with the Zoom link will be provided to registered attendees the week of the event.

Registration Rate:
Physicians: $75
Nurses & Allied Health Professionals: $75
Industry: $75


Tuition may be paid by Visa, MasterCard or check. Your email address is used for critical information, including registration confirmation, evaluation, and certificate. Be sure to include an email address that you check frequently. If you prefer to pay by phone or check, please contact the Stanford Center for CME at (650) 497-8554 for assistance.

STAP-eligible employees can use STAP funds towards the registration fees for this activity.  Complete the STAP Reimbursement Request Form and submit to your department administrator. 


Credits
AMA PRA Category 1 Credits™ (8.00 hours), Non-Physician Participation Credit (8.00 hours)

Target AudienceSpecialties - HematologyProfessions - Fellow/Resident, Non-Physician, Physician

Objectives
At the conclusion of this activity, participants should be able to:

  • Implement the use of new chemotherapeutics and biologics in subpopulations of acute myeloid leukemia patients based on patient clinical and genetic profiles
  • Review new drug approvals and practical considerations for their safe and optimal use
  • Evaluate optimal sequencing and combinations of novel agents for CLL and lymphomas
  • Asses the role of new therapies in non-malignant hematology indications
  • Discuss available therapeutic options for patients with low- or high-risk myelodysplastic syndromes and utilize the revised international prognostic scoring system (IPSS-R) with new mutation data to classify patients for treatment


Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Live Activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.